Collectively, BIDEN-AP and its nanoconjugate CCPM-BIDEN-AP represent a new class of agents that can effectively suppress tumor growth by promoting ligand-dependent forward EphB4 signaling in tumor cells and reduce angiogenesis by inhibiting reverse EFNB2 signaling in tumor-associated endothelial cells (Fig. 7D). The gene discussed is DHCR7-DT; the disease is neoplasm.